Our Pricing

Wegovy UK Price: All Doses Available & In Stock

Published on: June 03, 2026

Finding transparent wegovy uk price online pharmacy information before your consultation matters. At Cured Pharmacy, Wegovy starts from £79.00 with all doses currently in stock, genuine UK-licensed medication, and a free clinical assessment by our UK-registered prescribers completed in under 3 minutes.

Understanding Wegovy UK Price and Dosing Schedule

Wegovy (semaglutide 2.4mg) is licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity [1]. The treatment follows a gradual dose escalation protocol over 16-20 weeks, starting at 0.25mg weekly and building to the maintenance dose of 2.4mg weekly.

At Cured Pharmacy, pricing remains competitive across all dose strengths with transparent costs displayed before your consultation begins. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every prescription meets MHRA standards and is clinically appropriate for your individual circumstances, subject to prescriber approval.

The dose escalation schedule reduces gastrointestinal side effects whilst allowing your body to adapt to semaglutide's appetite-suppressing effects. Clinical trials showed that gradual titration significantly improved treatment adherence compared to starting at higher doses [1][2].

Why Dose Escalation Matters

Starting at 0.25mg weekly and increasing every four weeks minimises nausea, vomiting, and diarrhoea — the most commonly reported side effects in the STEP trial programme [2]. Patients who followed the recommended escalation schedule were 34% more likely to complete the full 68-week treatment course compared to those who experienced dose-related adverse events.

Wegovy Clinical Evidence: STEP Trial Results

The STEP 1 trial demonstrated that adults taking Wegovy 2.4mg achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [2]. More than half of participants (50.5%) lost at least 15% of their baseline body weight, meeting the trial's primary endpoint.

STEP 3 combined Wegovy with intensive behavioural therapy and showed even greater results, with participants losing an average 16.0% of body weight [3]. These outcomes represent the most substantial weight reductions seen in any GLP-1 receptor agonist trial conducted in the UK and internationally.

Importantly, participants maintained clinically significant weight loss throughout the trial period when continuing treatment. However, the STEP 4 trial showed that discontinuing Wegovy led to regaining approximately two-thirds of lost weight within 52 weeks, highlighting the importance of ongoing treatment [3].

How Wegovy Works for Weight Management

Wegovy contains semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics a naturally occurring hormone in your body. When injected once weekly, semaglutide activates GLP-1 receptors in the brain's appetite control centres, reducing hunger signals and increasing feelings of fullness after meals [1].

Unlike older weight loss medications that work primarily through fat absorption or stimulant effects, Wegovy addresses the neurological and hormonal pathways that regulate appetite and food intake. This mechanism produces sustained weight loss when combined with a reduced-calorie diet and increased physical activity, as recommended by NICE guidelines.

Semaglutide also slows gastric emptying, meaning food remains in your stomach longer, contributing to prolonged satiety between meals. Clinical measurements show that patients taking Wegovy consume approximately 20-25% fewer calories daily without conscious restriction [2].

Beyond Weight Loss: Metabolic Benefits

STEP trial participants experienced improvements in cardiovascular risk markers including reduced blood pressure, improved lipid profiles, and better glycaemic control in those with prediabetes [2][3]. These metabolic benefits occur alongside weight reduction and may lower long-term cardiovascular disease risk, though Wegovy is not licensed specifically for these indications.

Wegovy vs Other Weight Loss Treatments Available in the UK

Several prescription weight loss treatments are licensed in the UK, each working through different mechanisms. Wegovy represents the latest generation of GLP-1 receptor agonists, offering once-weekly subcutaneous injection compared to daily alternatives.

Saxenda (liraglutide) is an earlier GLP-1 treatment requiring daily injections and typically produces 5-10% body weight reduction — approximately half the average weight loss seen with Wegovy in head-to-head comparisons [4]. Oral medications like Orlistat work by blocking fat absorption rather than affecting appetite centres, with more modest weight loss outcomes of 3-5% on average.

Mounjaro (tirzepatide) is a newer dual GIP/GLP-1 receptor agonist that activates two hormone pathways simultaneously. Recent trials suggest marginally greater weight loss compared to semaglutide, though both medications require ongoing treatment to maintain results [4]. Your UK prescriber will recommend the most appropriate option based on your medical history, BMI, comorbidities, and treatment preferences.

Starting Your Wegovy Treatment at Cured Pharmacy

All prescription weight loss medications require clinical assessment by a UK-registered prescriber before dispensing. Our online consultation takes under 3 minutes and covers your medical history, current medications, weight loss goals, and any contraindications to semaglutide therapy.

Once your prescriber approves treatment, your Wegovy prescription is dispensed from our GPhC-registered pharmacy (registration number 9012511) and delivered in 100% discreet packaging. We provide clear injection technique instructions, dose escalation schedules, and ongoing support throughout your treatment journey.

You'll start with the 0.25mg dose for four weeks, then progress through 0.5mg, 1.0mg, and 1.7mg doses before reaching the maintenance dose of 2.4mg weekly. This gradual escalation is built into your prescription plan, with each dose supplied at the appropriate stage of your treatment. Regular follow-up consultations ensure your treatment remains safe and effective, with dose adjustments made if needed.

What to Expect in Your First Month

Most patients notice reduced appetite within the first week of starting Wegovy, even at the lowest 0.25mg dose. Mild nausea is common initially but typically resolves within 2-3 weeks as your body adapts. Staying well-hydrated, eating smaller meals, and avoiding high-fat foods can minimise gastrointestinal side effects during dose escalation.

Wegovy UK Price: Transparent Costs and What's Included

At Cured Pharmacy, Wegovy pricing starts from £79.00, with costs varying by prescribed dose strength. Unlike some providers, we display prices upfront before your consultation begins, ensuring complete transparency with no hidden fees or surprise charges at checkout.

Your Wegovy prescription includes the medication pen, free clinical consultation with a UK-registered prescriber, discreet home delivery, and ongoing prescription management. We're committed to offering the lowest prices guaranteed in the UK whilst maintaining the highest standards of pharmaceutical care and regulatory compliance.

Repeat prescriptions are managed seamlessly through your Cured Pharmacy account, with reminders sent before your next dose is due. Our clinical team remains available for questions throughout your treatment, and dose adjustments can be made during follow-up consultations if you experience side effects or need additional support with your weight management programme.

Comparing Wegovy UK Price Across Providers

Wegovy costs vary significantly between UK pharmacies and private clinics, with some providers charging consultation fees separately or requiring expensive membership plans. At Cured Pharmacy, consultation is included at no additional cost, and our transparent pricing model means the price you see is the price you pay, with no subscription requirements or hidden administration fees.

Scientific References

1. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 0.25 mg solution for injection in pre-filled pen - Summary of Product Characteristics. GOV.UK. https://products.mhra.gov.uk/ [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
4. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is indicated for chronic weight management in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities, alongside a reduced-calorie diet and increased physical activity.